Health care giantJohnson & Johnson said on Wednesday the US Food and Drug Administration (FDA) has approved its drug to treat patients aged 12 years and older with an immune-mediated disorder.

Atzumi combines a proprietary advanced powder and device technology to simplify nasal delivery of dihydroergotamine for acute treatment of migraine.

The U.S. Food and Drug Administration has approved Amneal Pharmaceuticals' self-administered migraine drug, giving way to a ...

The US Food and Drug Administration (FDA) has approved Neurelis’ diazepam nasal spray, Valtoco, for the short-term treatment of acute repetitive seizures, also referred to as seizure clusters ...

Previously called STS101, the company said Wednesday that the drug’s brand name is Atzumi and is indicated for acute migraine ...

New York, April 30, 2025 (GLOBE NEWSWIRE) -- Muscular Dystrophy Association (MDA) applauds the U.S. Food and Drug Administration (FDA ... more about this approval in Johnson & Johnson’s news ...

(RTTNews) - Johnson & Johnson (JNJ) announced the FDA has approved IMAAVY, a human FcRn-blocking monoclonal antibody, for the treatment of generalized myasthenia gravis. The approval is supported ...

New York, April 30, 2025 (GLOBE NEWSWIRE) -- Muscular Dystrophy Association (MDA) applauds the U.S. Food and Drug Administration (FDA) approval of IMAAVY ... Learn more about this approval in Johnson ...

New York, April 30, 2025 (GLOBE NEWSWIRE) -- Muscular Dystrophy Association (MDA) applauds the U.S. Food and Drug Administration (FDA) approval of IMAAVY ... Learn more about this approval in Johnson ...